Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Enveric Biosciences, Inc. - Common Stock
(NQ:
ENVB
)
1.200
-0.070 (-5.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 28, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Enveric Biosciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Enveric Biosciences Deepens Its Mental Health-Focused Pipeline With Library of Preclinical Compounds
February 21, 2024
Enveric Biosciences announced discovery of multiple compounds using its Psybrary platform and AI system. These compounds broaden their range of mental health treatments.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders
February 21, 2024
From
Enveric Biosciences
Via
Business Wire
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
February 15, 2024
Via
Benzinga
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
January 27, 2024
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...
Via
Benzinga
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
January 12, 2024
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
Via
Benzinga
30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond
January 10, 2024
The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substances like psilocybin and MDMA to treat mental health...
Via
Benzinga
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
January 07, 2024
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury
Via
Benzinga
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series
January 03, 2024
From
Enveric Biosciences
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
January 01, 2024
Via
Benzinga
Why Fisker Shares Are Trading Higher By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
December 29, 2023
Shares of Fisker Inc. (NYSE: FSR) rose sharply during Friday’s session after the company provided a December 2023 business update.
Via
Benzinga
Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market
December 29, 2023
From
Enveric Biosciences
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 28, 2023
Via
Benzinga
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series
December 28, 2023
From
Enveric Biosciences
Via
Business Wire
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
December 27, 2023
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also...
Via
Benzinga
Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373
December 27, 2023
From
Enveric Biosciences
Via
Business Wire
5 Biotech stocks tapping into unmet mental health treatment needs
December 20, 2023
Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments.
Via
MarketBeat
Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”
December 20, 2023
From
Enveric Biosciences
Via
Business Wire
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More
December 18, 2023
Biden To Decide On Psychedelic Therapy Bill
Via
Benzinga
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
December 11, 2023
John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy
Via
Benzinga
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
December 05, 2023
Defense Dept. Funds Ketamine Study For PTSD Treatment
Via
Benzinga
Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds
December 05, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
November 29, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry
November 27, 2023
From
Enveric Biosciences
Via
Business Wire
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
November 24, 2023
GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)
November 24, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences' Revenue Drops In Q3 2023 As Next-Gen Psychedelics Advance To Clinical Trials
November 14, 2023
Enveric Biosciences (NASDAQ: ENVB), a biopharma company developing novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, reported its...
Via
Benzinga
Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results
November 13, 2023
From
Enveric Biosciences, Inc.
Via
Business Wire
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
November 12, 2023
Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans?
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More
November 06, 2023
DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More
October 29, 2023
Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.